Brenntag (BNR) investor relations material

Executive summary

• Q2 2026 delivered robust operating performance and margin expansion, with sales up 11% year-over-year to EUR 4.3 billion, driven by strong pricing, disciplined execution, and structural cost savings.

• Operating gross profit rose 19% to EUR 1,146 million, and operating EBITDA surged 41% to EUR 463 million, reflecting higher prices and cost-out savings.

• Customer demand remained resilient, with stable volumes and secure product availability across Essentials and Specialties.

• Cost-out measures accelerated, achieving a EUR 41 million run rate in Q2 and targeting EUR 200–250 million by 2027.

• Bonus provisions increased significantly due to improved performance and higher sales incentives.

Financial highlights

• Sales reached EUR 4.3 billion in Q2 2026, up 11.1% year-over-year (FX adjusted), with Essentials outperforming Specialties.

• Operating gross profit was EUR 1,146 million (+18.9% vs. PY), and operating EBITDA was EUR 463 million (+40.9% vs. PY); margin improved to 40.4%.

• Free cash flow declined to EUR 4 million from EUR 154 million in Q2 2025, mainly due to higher working capital requirements.

• Net financial liabilities increased to EUR 3,100 million at June 30, 2026.

• Working capital turnover improved to 7.5x, reflecting efficient management.

Outlook and guidance

• Full-year 2026 operating EBITDA guidance was raised to EUR 1,350–1,450 million, reflecting strong performance and positive price trends.

• Guidance for H2 is conservative, expecting sequential moderation in gross profit and EBITDA as pricing benefits normalize.

• Macroeconomic environment remains uncertain, with continued volatility and risk of softer demand in H2.

• Cost savings initiatives are expected to continue, with a target of EUR 200–250 million by 2027.

• Comprehensive update on medium-term strategy to be presented at Capital Markets Day in November 2026.